The aim of this study is to use a multicenter, randomized, controlled trial to explore the efficacy and safety of combination therapy with afatinib plus HAD-B1 in the treatment of patients with locally advanced or metastatic NSCLC who have an activating EGFR mutation. Here, EGFR is linked to non-small cell lung carcinoma.